The civic record
Read. Follow. Verify.Maryland Bill Requires Insurers to Cover Long-Term Antibiotic Treatment for Lyme Disease
Last action · March 6, 2026: Hearing 3/13 at 1:00 p.m.Sponsor: Johnny Mautz
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
Maryland health insurers, nonprofit health service plans, and health maintenance organizations must provide coverage for the full duration of s prescribed by a licensed physician for Lyme disease and related tick-borne illnesses, starting January 1, 2027.
Patients undergoing extended antibiotic therapy for tick-borne infections gain mandated insurance protection against coverage caps and denials based on experimental treatment labels.
- Lyme disease is a tick-borne bacterial infection transmitted by blacklegged ticks carrying Borrelia burgdorferi, which can result in chronic symptoms for some patients requiring extended medical management. context
- State-level health insurance mandates establish minimum coverage requirements that commercial health insurance plans operating within the state jurisdiction must incorporate into their benefit packages. context
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Insurers and nonprofit health service plans
Must provide coverage for the full length of long-term antibiotic treatments prescribed for Lyme disease and related tick-borne illnesses without quantitative limits or experimental exclusions.
Health maintenance organizations
Must provide coverage for the full length of long-term antibiotic treatments prescribed for Lyme disease and related tick-borne illnesses without quantitative limits or experimental exclusions.
Licensed physicians
Can order long-term antibiotic treatments for therapeutic purposes that insurers are legally required to cover for their patients.
Patients with Lyme disease and related tick-borne illnesses
Gain guaranteed insurance coverage for long-term antibiotic treatments exceeding 4 weeks without quantitative limits or denials based on experimental status.
Key Facts
- Applies to insurers and nonprofit health service plans providing hospital, medical, surgical, or pharmaceutical benefits under policies issued or delivered in Maryland.
- Applies to health maintenance organizations providing hospital, medical, surgical, or pharmaceutical benefits under contracts issued or delivered in Maryland.
- Requires coverage for the full length of long-term antibiotic treatment when ordered by a licensed treating physician for therapeutic purposes.
- Prohibits insurers, nonprofit health service plans, and health maintenance organizations from imposing quantitative limitations on long-term antibiotic treatments.
Show all 10 facts
- Prohibits entities from denying coverage solely because a treatment is categorized as unproven, experimental, or investigational.
- Defines long-term antibiotic treatment as oral, intramuscular, or intravenous antibiotic medications administered for longer than 4 weeks.
- Includes within the definition of Lyme disease clinical diagnoses based on signs or symptoms of acute infection, late-stage or chronic infection, complications, CDC-recognized strains, CDC surveillance criteria, or clinical diagnoses by a licensed physician using medical history, physical examinations, or supportive testing data.
- Includes related tick-borne illnesses such as bartonellosis, babesiosis, ehrlichiosis, anaplasmosis, piroplasmosis, and other associated illnesses.
- Applies to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after January 1, 2027.
- Takes effect January 1, 2027.
Frequently Asked Questions
What types of insurance plans are covered under this bill?
Can insurers deny coverage by claiming long-term antibiotic treatment is experimental?
What is considered long-term antibiotic treatment under the legislation?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
3 actions- Mar 6, 2026SenateHearing 3/13 at 1:00 p.m.
- Mar 4, 2026SenateCommitteeRereferred to Finance
- Feb 13, 2026SenateIntroducedFirst Reading Senate Rules
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Prohibition of Experimental Classification Denials
The bill explicitly forbids insurers from denying coverage for long-term tick-borne illness treatments on the basis that they are experimental or investigational.
Connected Entities
Sources
mgaleg.maryland.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools
